OLUKOTUN ADEOYE Y sold $174K of ARWR

Stifel reduced its price target for Arrowhead Pharmaceuticals (ARWR) to $96 from $104, citing weaker-than-expected Tryngolza launch results. The stock has fallen 19% in a week, trading at $47.15. Despite this, Arrowhead and partner Ionis maintain confidence in peak sales targets. The company reported a wider loss for fiscal 2026, but revenue of $450.8 million exceeded expectations, driven by REDEMPLO launch momentum.

Arrowhead Pharmaceuticals (ARWR) reported FY2026 revenue of $450.8M, down from $829.4M, and a net loss of $724.2M. The company has $1.193B in cash and securities. Positive Phase 3 results for sHTG were announced, with a potential U.S. launch in Q2 2027. REDEMPLO for FCS was launched, and interim Phase 1/2a data for ARO-DIMER-PA showed reductions in various cholesterol and lipid levels. The average 12-month price target is $106.75, with 14 of 15 analysts rating it Buy.

Arrowhead (ARWR) reported progress in its REDEMPLO drug's market penetration, with 950 new patient prescriptions and 860 prescribers as of late. The company aims for a U.S. launch in sHTG in Q2 2027, expecting FDA review. Positive clinical data shows significant triglyceride reductions and pancreatitis risk reduction. ARWR projects $3B-$4B in annual U.S. sales for REDEMPLO in sHTG. The drug is also approved in Germany and the U.K.

Arrowhead Pharmaceuticals reported Q4 earnings, highlighting increased prescriptions for its drugs and potential future sales. The company expects $3B-$4B in annual U.S. sales for REDEMPLO if approved for SHTG. Operating expenses rose to $1.16B, but cash reserves increased to $1.2B. Arrowhead plans to track key metrics for an SHTG launch and has upcoming pipeline milestones in 2027.

Arrowhead Pharmaceuticals (ARWR) reported a net loss of $724.2 million for FY2026, down from $1.6 million in FY2025, due to a one-time expense and absence of prior-year collaboration revenue. Revenue was $450.8 million, down from $829.4 million. REDEMPLO (plozasiran) generated $6.6 million in product revenue. The company is preparing for a potential U.S. launch of REDEMPLO for severe hypertriglyceridemia (SHTG) in Q2 2027. Cash position was nearly $1.2 billion as of September 30, 2026.

Arrowhead Pharmaceuticals reported a fiscal 2026 net loss of $724.2M, down from $1.6M in 2025, with revenue at $450.8M, a 45.6% decrease. REDEMPLO (plozasiran) generated $6.6M in net product revenue. The company aims for a Q2 2027 launch of its SHTG indication, targeting $3B-$4B in annual sales. Management expects growth despite challenges in prescription conversion and payer coverage.